TARDBP and amyotrophic lateral sclerosis: Although findings from this study do not yet demonstrate efficacy, this trial has demonstrated safety in ALS patients with encouraging trends related to ALS Functional Rating Scale (ALSFRS), forced vital capacity, and ALS biomarkers (e.g., TDP-43, tau protein and SOD1) [18].